Business
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type patients, representing 80% of total patients - greatly exceeding the 48-50% for standard of care 12-month progression-free survival also markedly improved, with a 20% increase over standard of care iSCIB1+ Immunobody® selected for future development; planning for registrational Phase 2b/3 global stu
About this update from Scancell Holdings Plc
[{"type":"image","alt":"Scancell Holdings Plc","displaySize":"","headline":null,"caption":"Scancell Holdings Plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/b13bc6685f23fb28f74542b8ae6c6fee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FhJvhpDXvP8ngfWe1NUy2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b13bc6685f23fb28f74542b8ae6c6fee","width":300,"height":54}},"lazy":false},{"type":"text","content":"SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety","length":137,"tagName":"p"},{"type":"text","content":"Overall response rate for iSCIB1+ was 69% for target HLA type patients, representing 80% of total patients - greatly exceeding the 48-50% for standard of care","length":158,"tagName":"p"},{"type":"text","content":"12-month progression-free survival also markedly improved, with a 20% increase over standard of care ","length":100,"tagName":"p"},{"type":"text","content":"iSCIB1+ Immunobody® selected for future development; planning for registrational Phase 2b/3 global study accelerated","length":116,"tagName":"p"},{"type":"text","content":"Data provides option for patient selection biomarker for future registrational study","length":84,"tagName":"p"},{"type":"text","content":"Scancell to host presentation and Q&A on data at 13:00 BST","length":62,"tagName":"p"},{"type":"text","content":"NOTTINGHAM, United Kingdom, July 22, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of Immunobody® and Moditope® active immunotherapies to treat cancer, announces further positive data from the ongoing Phase 2 SCOPE trial of SCIB1/iSCIB1+ Immunobody® DNA active immunotherapies in combination with checkpoint inhibitors in patients with advanced unresectable melanoma. The data demonstrates a potential new benchmark for treatment of patients with late-stage melanoma in terms of efficacy, durability, immune responses and safety.","length":557,"tagName":"p"},{"type":"text","content":"Dr Heather Shaw, lead for the Medical Oncology Skin Cancer Service at University College London Hospital, London and principal investigator of the SCOPE trial, said: “The addition of SCIB1 or iSCIB1+ to standard-of-care checkpoint in...